Thymic carcinoma

Summary

Thymic carcinoma (MONDO:0006451) is a cancer (an umbrella term covering 9 Mondo subtypes) with 1 cohort gene (1 CIViC-evidence somatic driver) and 47 clinical trials. Molecularly, KIT D820E confers sensitivity to Sorafenib in Thymic Carcinoma (CIViC Level C); 5 further subtype–drug associations are mapped below. Top therapeutic interventions include cyclophosphamide anhydrous, ramucirumab, and avelumab.

At a glance

• Classification: Cancer
• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Umbrella term: 9 Mondo subtypes
• Cohort genes: 1
• Phenotypes (HPO): 13
• Clinical trials: 47
• Precision-medicine evidence (CIViC): 6 subtype–drug associations

Clinical features

Signs & symptoms

Clinical features (HPO)

13 HPO clinical features (Orphanet curated; top 13 by frequency):

HPO ID	Term	Frequency
HP:0100521	Neoplasm of the thymus	Very frequent (80-99%)
HP:0100721	Mediastinal lymphadenopathy	Very frequent (80-99%)
HP:0000969	Edema	Frequent (30-79%)
HP:0002094	Dyspnea	Frequent (30-79%)
HP:0005345	Abnormal vena cava morphology	Frequent (30-79%)
HP:0006597	Diaphragmatic paralysis	Frequent (30-79%)
HP:0012735	Cough	Frequent (30-79%)
HP:0100540	Palpebral edema	Frequent (30-79%)
HP:0100749	Chest pain	Frequent (30-79%)
HP:0000975	Hyperhidrosis	Occasional (5-29%)
HP:0001824	Weight loss	Occasional (5-29%)
HP:0003473	Fatigable weakness	Occasional (5-29%)
HP:0012378	Fatigue	Occasional (5-29%)

Identifiers

Disease identifiers

Field	Value
Canonical name	thymic carcinoma
Mondo ID	MONDO:0006451
EFO	EFO:1000576
Orphanet	99868
DOID	DOID:3284, DOID:4554
ICD-11	1351671383
NCIT	C7569, C7612
SNOMED CT	444374006
UMLS	C0205969
MedGen	60049
GARD	0019695
MedDRA	10061031
Anatomy (UBERON)	UBERON:0002370
Is cancer (heuristic)	yes

Also known as: carcinoma of thymus · malignant thymoma · THYC · thymic carcinoma · thymic carcinoma (excluding well differentiated thymic carcinoma) · thymic carcinoma excluding well differentiated thymic carcinoma · thymoma type C · thymoma, malignant · thymoma, malignant (morphologic abnormality) · thymoma, type C (morphologic abnormality) · thymus carcinoma · type C thymoma

Data availability: 4 cell lines.

Disease family

An umbrella term covering 9 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › immune system cancer › thymus cancer › thymic carcinoma

Related subtypes (1): thymus lymphoma

Subtypes (9): invasive malignant thymoma, thymus gland adenocarcinoma, thymus squamous cell carcinoma, malignant type AB thymoma, lymphoepithelioma-like thymic carcinoma, thymus clear cell carcinoma, thymic sarcomatoid carcinoma, thymic undifferentiated carcinoma, thymic neuroendocrine carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 18 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
KIT	Act	AML,GIST,MEL,MGCT	CIViC #29

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
KIT	Orphanet:102724	Acute myeloid leukemia with t(8;21)(q22;q22) translocation
KIT	Orphanet:158766	Typical urticaria pigmentosa
KIT	Orphanet:158769	Plaque-form urticaria pigmentosa
KIT	Orphanet:158772	Nodular urticaria pigmentosa
KIT	Orphanet:158775	Smoldering systemic mastocytosis
KIT	Orphanet:158778	Isolated bone marrow mastocytosis
KIT	Orphanet:280785	Bullous diffuse cutaneous mastocytosis
KIT	Orphanet:280794	Pseudoxanthomatous diffuse cutaneous mastocytosis
KIT	Orphanet:2884	Piebaldism
KIT	Orphanet:44890	Gastrointestinal stromal tumor
KIT	Orphanet:566393	Acute mast cell leukemia
KIT	Orphanet:566396	Chronic mast cell leukemia
KIT	Orphanet:79455	Cutaneous mastocytoma
KIT	Orphanet:842	Testicular seminomatous germ cell tumor
KIT	Orphanet:90389	Telangiectasia macularis eruptiva perstans
KIT	Orphanet:98829	Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
KIT	Orphanet:98834	Acute myeloblastic leukemia with maturation
KIT	Orphanet:98849	Systemic mastocytosis with associated hematologic neoplasm

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
KIT	HGNC:6342	ENSG00000157404	P10721	Mast/stem cell growth factor receptor Kit	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
KIT	Mast/stem cell growth factor receptor Kit	Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell develo…

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	27.7×	0.036

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
KIT	Kinase	yes	2.7.10.1	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Tyr_kinase_rcpt_3_CS

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
lateral nuclear group of thalamus	1
oocyte	1
secondary oocyte	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
KIT	263	broad	marker	lateral nuclear group of thalamus, secondary oocyte, oocyte

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
KIT	6,087

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
KIT	P10721	52

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 39. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Dasatinib-resistant KIT mutants	1	11420.0×	3e-04	KIT
Imatinib-resistant KIT mutants	1	11420.0×	3e-04	KIT
KIT mutants bind TKIs	1	11420.0×	3e-04	KIT
Masitinib-resistant KIT mutants	1	11420.0×	3e-04	KIT
Nilotinib-resistant KIT mutants	1	11420.0×	3e-04	KIT
Regorafenib-resistant KIT mutants	1	11420.0×	3e-04	KIT
Signaling by kinase domain mutants of KIT	1	11420.0×	3e-04	KIT
Sunitinib-resistant KIT mutants	1	11420.0×	3e-04	KIT
Signaling by juxtamembrane domain KIT mutants	1	11420.0×	3e-04	KIT
Sorafenib-resistant KIT mutants	1	11420.0×	3e-04	KIT
Drug resistance of KIT mutants	1	11420.0×	3e-04	KIT
Signaling by extracellular domain mutants of KIT	1	11420.0×	3e-04	KIT
Signaling by KIT in disease	1	1142.0×	0.003	KIT
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	1	761.3×	0.004	KIT
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	1	634.4×	0.004	KIT
Developmental Lineage of Mammary Gland Alveolar Cells	1	634.4×	0.004	KIT
Regulation of KIT signaling	1	601.0×	0.004	KIT
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	1	519.1×	0.004	KIT
Developmental Lineage of Mammary Gland Luminal Epithelial Cells	1	456.8×	0.004	KIT
PI3K/AKT Signaling in Cancer	1	368.4×	0.005	KIT
Negative regulation of the PI3K/AKT network	1	278.5×	0.007	KIT
Signaling by SCF-KIT	1	248.3×	0.007	KIT
Transcriptional and post-translational regulation of MITF-M expression and activity	1	178.4×	0.010	KIT
MAPK1/MAPK3 signaling	1	131.3×	0.012	KIT
Constitutive Signaling by Aberrant PI3K in Cancer	1	126.9×	0.012	KIT
MITF-M-regulated melanocyte development	1	114.2×	0.013	KIT
MAPK family signaling cascades	1	102.9×	0.014	KIT
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	1	96.8×	0.014	KIT
Intracellular signaling by second messengers	1	91.4×	0.015	KIT
PIP3 activates AKT signaling	1	66.8×	0.019	KIT

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
melanocyte adhesion	1	16852.0×	0.001	KIT
positive regulation of pyloric antrum smooth muscle contraction	1	16852.0×	0.001	KIT
positive regulation of colon smooth muscle contraction	1	16852.0×	0.001	KIT
positive regulation of vascular associated smooth muscle cell differentiation	1	8426.0×	0.001	KIT
Fc receptor signaling pathway	1	5617.3×	0.001	KIT
Kit signaling pathway	1	5617.3×	0.001	KIT
melanocyte migration	1	5617.3×	0.001	KIT
obsolete regulation of bile acid metabolic process	1	5617.3×	0.001	KIT
positive regulation of small intestine smooth muscle contraction	1	5617.3×	0.001	KIT
mast cell chemotaxis	1	4213.0×	0.001	KIT
hematopoietic stem cell migration	1	4213.0×	0.001	KIT
mast cell differentiation	1	4213.0×	0.001	KIT
positive regulation of dendritic cell cytokine production	1	3370.4×	0.001	KIT
positive regulation of mast cell cytokine production	1	3370.4×	0.001	KIT
mast cell proliferation	1	3370.4×	0.001	KIT
positive regulation of mast cell proliferation	1	3370.4×	0.001	KIT
lymphoid progenitor cell differentiation	1	2808.7×	0.001	KIT
erythropoietin-mediated signaling pathway	1	2808.7×	0.001	KIT
myeloid progenitor cell differentiation	1	2407.4×	0.001	KIT
immature B cell differentiation	1	2407.4×	0.001	KIT
glycosphingolipid metabolic process	1	2407.4×	0.001	KIT
tongue development	1	2106.5×	0.001	KIT
primordial germ cell migration	1	1872.4×	0.001	KIT
positive regulation of long-term neuronal synaptic plasticity	1	1872.4×	0.001	KIT
negative regulation of developmental process	1	1872.4×	0.001	KIT
negative regulation of reproductive process	1	1685.2×	0.002	KIT
positive regulation of pseudopodium assembly	1	1296.3×	0.002	KIT
embryonic hemopoiesis	1	991.3×	0.003	KIT
detection of mechanical stimulus involved in sensory perception of sound	1	936.2×	0.003	KIT
ectopic germ cell programmed cell death	1	842.6×	0.003	KIT

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Amrubicin, Avelumab, Belinostat, Carboplatin, Cisplatin, Epacadostat, Erfonrilimab, Lenvatinib, Paclitaxel, Pembrolizumab, Ramucirumab, Sacituzumab Govitecan, Sunitinib.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
KIT	PONATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
KIT	99	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
PONATINIB	4	KIT
FEDRATINIB	4	KIT
TIVOZANIB	4	KIT
LENVATINIB	4	KIT
AXITINIB	4	KIT
SORAFENIB	4	KIT
DASATINIB ANHYDROUS	4	KIT
NICLOSAMIDE	4	KIT
IMATINIB MESYLATE	4	KIT
RUXOLITINIB	4	KIT
INFIGRATINIB PHOSPHATE	4	KIT
INFIGRATINIB	4	KIT
REGORAFENIB	4	KIT
ENTRECTINIB	4	KIT
CABOZANTINIB	4	KIT
CERITINIB	4	KIT
VANDETANIB	4	KIT
NILOTINIB	4	KIT
BOSUTINIB	4	KIT
BRIGATINIB	4	KIT
PEXIDARTINIB	4	KIT
AVAPRITINIB	4	KIT
RIPRETINIB	4	KIT
PAZOPANIB	4	KIT
NINTEDANIB	4	KIT
SUNITINIB	4	KIT
DASATINIB	4	KIT
ERLOTINIB	4	KIT
QUIZARTINIB	4	KIT
CRIZOTINIB	4	KIT

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
KIT	2,305	Binding:2242, ADMET:32, Functional:22, Toxicity:9

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
KIT	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
KIT	2,305

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

28 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
PONATINIB	4	KIT
FEDRATINIB	4	KIT
TIVOZANIB	4	KIT
LENVATINIB	4	KIT
AXITINIB	4	KIT
SORAFENIB	4	KIT
DASATINIB ANHYDROUS	4	KIT
NICLOSAMIDE	4	KIT
IMATINIB MESYLATE	4	KIT
RUXOLITINIB	4	KIT
INFIGRATINIB PHOSPHATE	4	KIT
INFIGRATINIB	4	KIT
ENTRECTINIB	4	KIT
CABOZANTINIB	4	KIT
CERITINIB	4	KIT
VANDETANIB	4	KIT
NILOTINIB	4	KIT
BOSUTINIB	4	KIT
BRIGATINIB	4	KIT
PEXIDARTINIB	4	KIT
AVAPRITINIB	4	KIT
RIPRETINIB	4	KIT
PAZOPANIB	4	KIT
NINTEDANIB	4	KIT
DASATINIB	4	KIT
ERLOTINIB	4	KIT
QUIZARTINIB	4	KIT
CRIZOTINIB	4	KIT

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	KIT
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 47.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	29
Not specified	8
PHASE1	6
PHASE1/PHASE2	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06402708	PHASE3	RECRUITING	Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
NCT01025089	PHASE2	ACTIVE_NOT_RECRUITING	Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
NCT03076554	PHASE2	ACTIVE_NOT_RECRUITING	A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
NCT03134118	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
NCT03463460	PHASE2	ACTIVE_NOT_RECRUITING	Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
NCT06019468	PHASE2	RECRUITING	Neoadjuvant Treatment For Locally Advanced Thymic Cancer
NCT06248515	PHASE2	RECRUITING	A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
NCT06838910	PHASE2	RECRUITING	Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
NCT06980077	PHASE2	RECRUITING	Ivonescimab for the Treatment of Thymic Cancer
NCT07324629	PHASE2	NOT_YET_RECRUITING	Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
NCT07479628	PHASE2	NOT_YET_RECRUITING	Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma
NCT07598955	PHASE1/PHASE2	RECRUITING	Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
NCT00003662	PHASE2	COMPLETED	Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases
NCT00010257	PHASE2	COMPLETED	Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
NCT00198133	PHASE2	COMPLETED	Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
NCT00589290	PHASE2	COMPLETED	Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage
NCT00818090	PHASE2	TERMINATED	Paclitaxel and Cisplatin for Thymic Neoplasm
NCT00965250	PHASE2	COMPLETED	Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
NCT01011439	PHASE2	TERMINATED	Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
NCT01100944	PHASE1/PHASE2	TERMINATED	A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
NCT01301391	PHASE2	TERMINATED	Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
NCT01364727	PHASE2	COMPLETED	A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
NCT02062632	PHASE2	TERMINATED	Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
NCT02307500	PHASE2	COMPLETED	Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
NCT02364076	PHASE2	UNKNOWN	Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
NCT02623127	PHASE2	COMPLETED	A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma
NCT03449173	PHASE2	UNKNOWN	Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)
NCT03583086	PHASE1/PHASE2	COMPLETED	Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
NCT03694002	PHASE2	COMPLETED	Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
NCT03921671	PHASE2	UNKNOWN	Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
NCT04469725	PHASE2	TERMINATED	KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma
NCT04710628	PHASE2	COMPLETED	Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents
NCT04925947	PHASE2	TERMINATED	A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors
NCT07118176	PHASE1	RECRUITING	Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
NCT07181720	PHASE1	RECRUITING	CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
NCT00314873	PHASE1	COMPLETED	Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma
NCT01143545	PHASE1	TERMINATED	Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
NCT03517488	PHASE1	COMPLETED	A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
NCT04430842	PHASE1	COMPLETED	Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
NCT01385722	Not specified	ENROLLING_BY_INVITATION	Molecular Analysis of Thoracic Malignancies

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOPHOSPHAMIDE ANHYDROUS	4	4
RAMUCIRUMAB	4	2
AVELUMAB	4	1
BELINOSTAT	4	1
BUSULFAN	4	1
DOXEPIN HYDROCHLORIDE	4	1
REGORAFENIB	4	1
SACITUZUMAB GOVITECAN	4	1
SUNITINIB	4	1
ERFONRILIMAB	3	2
AMRUBICIN	3	1
EPACADOSTAT	3	1
IVONESCIMAB	3	1
SACITUZUMAB TIRUMOTECAN	3	1
FAPI-46 GA-68	2	1
RIMIDUCID	2	1
VOROLANIB	2	1
VUDALIMAB	2	1
MILCICLIB MALEATE	1	2
CHEMBL1200462	0	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 6 predictive associations from 6 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
KIT D820E	Sorafenib	Sensitivity/Response	CIViC C	EID7356
KIT P577_D579DEL	Sorafenib	Sensitivity/Response	CIViC C	EID7360
KIT V559G	Imatinib Mesylate	Sensitivity/Response	CIViC C	EID7357
KIT V560DEL	Imatinib	Sensitivity/Response	CIViC C	EID486
KIT V560DEL	Imatinib Mesylate	Sensitivity/Response	CIViC C	EID7359
KIT Y553N	Imatinib Mesylate	Sensitivity/Response	CIViC C	EID7358